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Transgenic expression of activated AKT1 in the murine prostate induces prostatic intraepithelial neoplasia
(PIN) that does not progress to invasive prostate cancer (CaP). In luminal epithelial cells of Akt-driven PIN,
we show the concomitant induction of p27Kip1 and senescence. Genetic ablation of p27Kip1 led to downregu-
lation of senescence markers and progression to cancer. In humans, p27Kip1 and senescence markers were
elevated in PIN not associated with CaP but were decreased or absent, respectively, in cancer-associated PIN
and in CaP. Importantly, p27Kip1 upregulation in mouse and human in situ lesions did not depend upon mTOR
or Akt activation but was instead specifically associated with alterations in cell polarity, architecture, and
adhesion molecules. These data suggest that a p27Kip1-driven checkpoint limits progression of PIN to CaP.INTRODUCTION
Activation of AKT through deregulated phosphatidylinositol 3-
kinase (PI3K) signaling resulting from genetic inactivation of
phosphatase and tensin homolog (PTEN), mutational activation
of PI3K, or the activation of upstream oncogenic tyrosine kinases
is a frequent molecular event in human cancer (Brugge et al.,
2007; Lee et al., 2007). We have previously shown that trans-
genic expression of activated Akt in the murine prostate induces
a uniform and highly penetrant prostatic intraepithelial neoplasia146 Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc.(PIN) phenotype confined to the ventral prostate (Majumder
et al., 2003). Even after long-term follow-up, these mice do not
develop invasive cancers. However, in this model, there is robust
and predictable time-dependent regression of the PIN with the
mTOR inhibitor RAD001 (Majumder et al., 2004). This model
thus provides a robust system in which to define transition steps
leading from PIN to invasive cancer.
In human epithelial cancers, reduced levels of p27Kip1 expres-
sion are frequently observed (Slingerland and Pagano, 2000)
and are correlated with tumor progression and poor survivalSIGNIFICANCE
Most human epithelial cancers progress from dysplastic in situ lesions to invasive and ultimately metastatic disease. Pros-
tatic intraepithelial neoplasia (PIN) is a precursor of invasive prostate cancer, but the molecular mechanisms underpinning
this transition are largely unknown. Here we define loss of p27Kip1 expression as a key event in this progression of PIN to
invasive cancer. We further show that p27Kip1 upregulation in PIN correlates with senescence in both murine and human
prostate tissue. Upregulation of p27Kip1 in preinvasive lesions is not dependent on mTOR or Akt activation but is secondary
to loss of cell polarity and disruption of cell-cell adhesions. We suggest that the p27Kip1-dependent checkpoint limits the
progression of PIN to invasive cancer.
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p27Kip1 Checkpoint Induces Senescence in PIN(Loda et al., 1997; Porter et al., 1997; Yang et al., 1998). p27Kip1
functions primarily as a negative regulator of cyclin-CDK activity
and thus likely participates in tumor suppression by inhibiting
cell-cycle progression (reviewed in Chu et al., 2008). Targeted
disruption of p27Kip1 (Cdkn1b/) in mice leads to prostatic hy-
perplasia (Cordon-Cardo et al., 1998) and development of pitui-
tary adenomas (Fero et al., 1996, 1998) as the mice age. How-
ever, Cdkn1b/ mice do not typically develop other
spontaneous tumors (Fero et al., 1996; Kiyokawa et al., 1996;
Nakayama et al., 1996).
In many human cancer cells, oncogene-induced senescence
(OIS) is associated with known tumor suppressor pathways
such as p53, VHL, and Rb (Serrano et al., 1997; Young et al.,
2008). It has been reported that OIS occurs in many human
and mouse precursors of cancer and that this phenomenon
can be reversed by the inactivation of tumor suppressor path-
ways (Braig et al., 2005; Chen et al., 2005; Collado et al., 2005;
Michaloglou et al., 2005). Recently, Young et al. (2008) have re-
ported that senescence induced by loss of VHL in renal cancer
cells is Rb, p27Kip1, and SKP2 dependent but p53 independent.
Here, we have investigated the role of p27Kip1 in tumor sup-
pression in prostate cancer. Using both genetically engineered
mice and human prostate samples, we have identified a relation-
ship among senescence induction, p27Kip1 expression, and PIN
that supports the notion that p27Kip1 induction in the context of
early neoplastic lesions may represent a preinvasive checkpoint
linked to cellular senescence.
Figure 1. Induction of p27Kip1 and Senescence in
Prostatic Intraepithelial Neoplasia of AKT1-Trans-
genic and PtenL/L;Cre+ Mice
(A) Ventral prostates (VPs) from wild-type (WT) and AKT1-
transgenic (AKT1-Tg) mice were stained by immunohisto-
chemistry using antibodies directed against phospho-Akt
(S473) (upper panels) or p27Kip1 (lower panels). Scale bar =
50 mM.
(B) The number of cells staining positive for p27Kip1 was deter-
mined in VPs of WT and AKT1-Tg mice of the indicated ages.
Data are presented as mean ± SEM.
(C) Wild-type (PtenL/L;Cre) and Pten conditional knockout
(prostate-specific) (PtenL/L;Cre+) VPs were stained with anti-
phospho-Akt (S473) (upper panels) or anti-p27Kip1 (lower
panels). Scale bar = 50 mM (100 mM in insert).
(D) Western blot analysis of p27Kip1 and tubulin in whole-
cell lysates from VPs of WT, Pten conditional knockout
(PtenL/L;Cre+), and AKT1-Tg mice at 6 weeks of age.
(E) VPs from WT and AKT1-Tg mice were stained with anti-
body against HP1a. Scale bar = 50 mM.
(F) The area of HP1a staining was measured in both WT and
AKT1-Tg prostates. Data are presented as mean ± SD.
RESULTS
p27Kip1 Protein and Markers
for Cellular Senescence Are Increased
in AKT1-Transgenic Prostate
Transgenic animals expressing activated Akt
(AKT1-Tg) in the ventral prostate (VP) uniformly
develop intraductal/intra-acinar lesions consistent
with PIN. However, progression to invasive pros-
tate cancer (CaP) has not been observed after 2 years of obser-
vation (data not shown). Moreover, despite the strong prolifera-
tive signal delivered by activated Akt in vitro, AKT1-Tg prostate
shows only a modest increase in BrdU incorporation, suggest-
ing a possible upregulation of cyclin-dependent kinase inhibi-
tors (Majumder et al., 2004). Thus, to determine the level of
p27Kip1 in the VP of AKT1-Tg mice, we performed immunohisto-
chemical (IHC) analysis using anti-p27Kip1. While activation of
Akt is associated with downregulation of p27Kip1 in a number
of in vitro systems (Liang et al., 2002; Shin et al., 2002; Viglietto
et al., 2002), surprisingly, p27Kip1 protein levels were signifi-
cantly higher in prostate epithelial cells expressing Myr-AKT1
when compared to littermate wild-type (WT) mice (Figures 1A
and 1D). Similarly, significant levels of elevated p27Kip1 protein
were observed in the VP of AKT1-Tg mice at 35, 45, and 60
days (Figure 1B).
We previously observed that PIN lesions in AKT1-Tg and Pten
heterozygous (+/) mice are histologically similar (Majumder
et al., 2003). In the latter, activation of Akt is seen in conjunction
with PTEN loss in PIN lesions (Majumder et al., 2003). Thus, we
next examined mice harboring two floxed Pten alleles and
a transgene driving the expression of prostate-restricted Cre
(ARR2PB-Cre) (referred to as PtenL/L;Cre+) (Wang et al.,
2003). We found that the development of PIN at 6 weeks of
age was accompanied by phosphorylation and activation of
Akt as well as a concomitant increase in p27Kip1 protein when
compared to littermate controls (Figures 1C and 1D). TheseCancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc. 147
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p27Kip1 Checkpoint Induces Senescence in PINdata suggest that p27Kip1 is upregulated in the context of PIN
driven either by myristoylation-dependent Akt activation or by
loss of PTEN.
Cellular senescence is commonly seen in the early or precur-
sor stages of invasive cancer (Braig et al., 2005; Chen et al.,
2005; Collado et al., 2005; Michaloglou et al., 2005). To deter-
mine whether cells in the PIN lesions found in AKT1-Tg mice
were senescent, we stained tissue sections for senescence-
associated b-galactosidase (b-gal) in frozen tissue samples or
for antibodies against HP1a and HP1g in paraffin-embedded
tissue (Bartkova et al., 2006). We found that the stabilization
of p27Kip1 protein was associated with the increased levels of
HP1a, HP1g, and b-gal activity in the PIN lesions of the
AKT1-Tg mice (Figures 1E and 1F; Figures 2A and 2B; data
not shown).
Figure 2. Genetic Inactivation ofCdkn1bRescues Cells from Senes-
cence and Increases Proliferation in AKT1-Transgenic Mice
(A–L) Twelve hours after BrdU administration, mice were sacrificed, and VPs
of WT (A, E, and I), AKT1-Tg (B, F, and J), Cdkn1b+/ (C, G, and K), and
AKT1-Tg/Cdkn1b+/ (D, H, and L) mice were stained with b-gal (A–D), hema-
toxylin and eosin (E–H), or anti-BrdU antibody (I–L). Scale bar = 50 mM
(100 mM in insert).
(M) The number of BrdU-stained cells per 100 ducts was determined by
manual counting of BrdU-positive cells in all VP lobes. Data are presented
as mean ± SD.148 Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc.Loss of p27Kip1 in AKT1-Tg Mice Rescues Cells from
Senescence and Increases Proliferation in Prostate
Epithelial Cells
It has been reported that oncogenes induce senescence in dif-
ferent human and murine precursors of cancer as well as in tu-
mors harboring deletion of the Pten tumor suppressor (Braig
et al., 2005; Chen et al., 2005; Collado et al., 2005; Michaloglou
et al., 2005). Senescence induced by Pten deficiency has been
reported to be dependent on p53. Inactivation of Pten causes
cellular senescence, and combined inactivation of Pten and
p53 causes a lethal form of invasive prostate cancer (Chen
et al., 2005). To test the hypothesis that the senescence ob-
served in the PIN lesions of the AKT1-Tg mice could be reversed
by the inactivation of the tumor suppressor p27Kip1, compound
mice were generated wherein Myr-AKT1 was expressed in
both the Cdkn1b heterozygous and homozygous null settings.
PIN in the VP of AKT1-Tg mice displayed high b-gal activity
(Figure 2B), and both HP1a and HP1g were elevated (Figures
1D and 1E; data not shown). However, b-gal activity as well as
expression of HP1a and HP1g was decreased in the PIN lesions
of mice in which AKT1 was expressed in the context of the
Cdkn1b heterozygous or homozygous background (Figures 2C
and 2D; data not shown). These data suggest that the PIN-in-
duced cellular senescence checkpoint is dependent on p27Kip1.
These findings also raised the possibility that p27Kip1-induced
senescence results in a block in cell-cycle progression and con-
sequently a failure to progress beyond the PIN phenotype. After
administration of BrdU, VPs from 10- to 16-week-old offspring
were harvested, and the rate of proliferation was determined
by IHC detection of incorporated BrdU. Indeed, VPs from
AKT1-Tg/Cdkn1b+/ and AKT1-Tg/Cdkn1b/ mice showed
significantly increased rates of BrdU incorporation (Figures 2L
and 2M) as compared with AKT1-Tg/Cdkn1b+/+, AKT1-WT/
Cdkn1b+/, AKT1-WT/Cdkn1b/, and AKT1-WT/Cdkn1b+/+
prostates (Figures 2I–2K and 2M; data not shown). At 10–16
weeks of age, the PIN phenotype was exacerbated, but no addi-
tional cancer phenotype was observed at this time point (Figures
2E–2H). Thus, at early time points, loss of Cdkn1b abrogates the
induction of senescence and results in increased prostate epi-
thelial cell proliferation in the setting of Akt activation.
AKT1-Tg Mice Harboring Loss of Either One or Both
Cdkn1b Alleles Develop Invasive Prostate Cancer
These observations were consistent with the notion that p27Kip1
acts as a checkpoint that limits hyperplastic proliferation and
malignant transformation. To determine whether p27Kip1 loss
also results in the progression from PIN to invasive CaP, we ex-
amined VPs of all genotypes resulting from the intercross of
AKT1-Tg/Cdkn1b+/ mice as the mice aged. As predicted,
AKT1-Tg/Cdkn1b+/ and AKT1-Tg/Cdkn1b/ mice, but not lit-
termate controls or AKT1-Tg/Cdkn1b+/+ mice, developed inva-
sive cancer in the VP (Figures 3A, 3B, and 3E; data not shown).
Thirty-nine percent of AKT1-Tg/Cdkn1b+/ mice and 57% of
AKT1-Tg/Cdkn1b/ mice developed invasive CaP at the age
of 1 year or more as compared with their control littermates
(Figure 3E). One AKT1-Tg/Cdkn1b+/ and one AKT1-Tg/
Cdkn1b/ mouse developed a tumor in the VP prior to 1 year
of age (Figure 3E; data not shown).
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p27Kip1 Checkpoint Induces Senescence in PINLoss of the basal epithelial cell layer and hence loss of expres-
sion of the basal cell-specific marker p63 is a distinguishing fea-
ture of the transition from PIN (p63+) to invasive CaP (p63) in
humans (Signoretti et al., 2000). We therefore examined p63 ex-
pression in murine prostate tumors by IHC. While basal cells
were present in the PIN lesions in VPs of AKT1-Tg mice
(Figure 3C), prostate tumors from AKT1-Tg/Cdkn1b+/ and
AKT1-Tg/Cdkn1b/ mice (Figure 3D; data not shown) lacked
the basal cell layer, confirming the invasiveness of these tumors.
To further characterize the tumor phenotype, we examined the
expression of the androgen receptor (AR) and the luminal cyto-
keratin 19 (CK19) by IHC and found that the tumors expressed
readily detectable AR and CK19 (see Figures S1A and S1B avail-
able online; data not shown) but failed to express cytokeratin 14
and p63 (Figure 3D; data not shown). These observations dem-
onstrate the luminal nature of these tumors, which is similar to
human prostate cancer. Finally, BrdU incorporation assays
showed that, as was the case in the PIN lesions arising in
AKT1-Tg/Cdkn1b+/ and AKT1-Tg/Cdkn1b/ mice, the result-
ing tumors were also highly proliferative (Figures S1C–S1F).
IHC and immunoblot analysis of p27Kip1 suggested that these tu-
mors retained the second allele of p27Kip1, though protein levels
were markedly reduced (Figures S2D–S2F and S2J). We noted
that Akt expression was reduced in these tumors due to varie-
gated expression of the transgene rather than to reduction of
Akt on a per cell basis (data not shown).
Figure 3. Genetic Inactivation of Cdkn1b in AKT1-Transgenic Mice
Results in Development of Invasive Prostate Cancer
(A) Prostatic intraepithelial neoplasia (PIN) in a representative section from the
VP of an AKT1-Tg mouse (52 weeks old). Scale bar = 100 mM.
(B) Invasive prostate cancer (CaP) in a representative section from an AKT1-
Tg/Cdkn1b+/ mouse. Sections were stained with H&E. Scale bar = 100 mM.
(C) VP from an AKT1-Tg mouse stained with antibodies directed against p63.
Scale bar = 100 mM.
(D) VP from an AKT1-Tg/Cdkn1b+/ mouse stained with antibodies directed
against p63. Scale bar = 100 mM.
(E) Summary of tumor incidence by age and genotype.Stabilization of p27Kip1 Is Dependent on the PIN
Phenotype
The finding that p27Kip1 levels were increased in the AKT1-Tg
mice raised the possibility that Akt activity might directly lead
to elevated levels of p27Kip1. Alternatively, p27Kip1 elevation
might be associated with activation of the mTOR kinase or
p70S6K pathways further downstream of Akt. To distinguish
among these possibilities, we took advantage of the mTOR de-
pendence of this PIN phenotype. Specifically, inhibition of
mTOR activity using the rapamycin derivative RAD001 (everoli-
mus) leads to the resolution of the PIN phenotype by day 14 of
treatment (Majumder et al., 2004). By comparing RAD001- and
placebo-treated AKT1-Tg and wild-type mice, we hoped to dis-
tinguish the contribution of three possible effectors of p27Kip1 in-
duction, namely the PIN phenotype itself (present or absent),
mTOR (active or inactive), and Akt (active or inactive). To this
end, 8- to 12-week-old AKT1-Tg and littermate wild-type mice
were treated with placebo or RAD001 for 2 or 14 days. Consis-
tent with our previous findings, 14 days after treatment, the VP
histology of RAD001-treated AKT1-Tg mice reverted to normal
(Figures 4A–4C; data not shown), while PIN persisted in pla-
cebo-treated AKT1-Tg mice (data not shown) and in mice
treated with RAD001 for 2 days (Figure 4B).
We next examined p27Kip1 in the VP of AKT1-Tg mice treated
with placebo or RAD001. Elevated levels of p27Kip1 were ob-
served in the VP of AKT1-Tg mice treated with placebo (Figures
4P–4R) and AKT1-Tg mice treated with RAD001 for 2 days (Fig-
ures 4M and 4N). However, p27Kip1 levels reverted to normal af-
ter 14 days of treatment, concomitant with the disappearance of
the PIN phenotype (Figures 4O and 4C). In AKT1-Tg animals,
mTOR inhibition leads to the loss of phosphorylation of both
eIF4G and S6 ribosomal protein (S6RP). In these experiments,
S6RP phosphorylation was inhibited after 2 days of treatment
with RAD001 (Figures 4H and 4I); however, p27Kip1 levels were
unaffected (compare Figures 4M and 4N). As we had previously
shown, the activation of Akt was unaffected by treatment with
RAD001 and persisted on day 14, at which time both the PIN
phenotype and the induction of p27Kip1 had resolved (Majumder
et al., 2004; Figures 4D–4F). Thus, Akt oncogenic activity by
itself is not sufficient for p27Kip1 induction (compare Figures 4F
and 4O).
Finally, we have used expression profiling to identify two
classes of transcripts indicative of either mTOR pathway acti-
vation (Majumder et al., 2004) or a distinct set of transcripts
correlated with the presence or absence of the PIN phenotype.
Aldolase 3 (a Hif-1 target) and prostate stem cell antigen
(PSCA) are prototypical members of each class of transcripts,
respectively. Consistent with the notion that p27Kip1 protein in-
duction is linked to the PIN phenotype, elevated p27Kip1 levels
correlated best with the pattern of mRNA induction seen with
the phenotype marker PSCA and senescence markers rather
than with the pharmacodynamic marker of mTOR activity aldol-
ase 3 (Figure S3, upper panel). Together, these data, summa-
rized in the lower panel of Figure S3, suggest that the cellular
or morphological alterations secondarily arising during the for-
mation of the PIN lesion either alone or together with activation
of Akt lead to the induction of p27Kip1 followed by cellular se-
nescence and a resulting block in both cell proliferation and
phenotype progression.Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc. 149
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p27Kip1 Checkpoint Induces Senescence in PINA prediction that follows from these findings is that this puta-
tive p27Kip1 checkpoint might be activated in PIN lesions that
are induced independently of PI3K pathway activation. Indeed,
we also found significant elevation of p27Kip1 in the PIN
phenotype of VPs of c-Myc-transgenic (Myc-Tg) mice as com-
pared to wild-type controls (Figures S4A and S4B). The
Myc-Tg mice developed invasive CaP at the age of 12 months,
and in these cancers, p27Kip1 appeared to be downregulated
as reported in human CaP (Figures 5F and 5G; Figures S4A
and S4B). Thus, the p27Kip1 checkpoint correlates best with
the appearance of PIN lesions.
Figure 4. Induction of p27Kip1 and Increases in Senescence Markers
Do Not Require mTOR Activation and Are Correlated with the PIN
Phenotype
AKT1-Tg mice were treated orally with RAD001 at 10 mg/kg per day (A–O) or
with placebo (P–R) for 0, 2, and 14 days. Shown are sections representative of
results obtained in at least 12 animals evaluated after each specific treatment
period. Scale bar = 100 mM in (A)–(I) and (M)–(R); scale bar = 200 mM in (J)–(L).
(A–C) Tissue sections from VPs stained with H&E.
(D–F) Tissue sections stained with antibody directed against phospho-Akt
(S473).
(G–I) Tissue sections stained with antibody directed against phospho-S6RP.
(J–L) Immunohistochemical analysis was performed in tissue sections with
antibody against HP1a.
(M–R) Tissue sections stained with antibody directed against p27Kip1.150 Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc.The Relevance of p27Kip1 Elevation in Human PIN
Levels of p27Kip1 in representative foci of human benign prostatic
epithelium, PIN, and invasive cancer were evaluated by IHC
analysis. The level of p27Kip1 was significantly reduced in inva-
sive cancer compared with benign epithelium (Figures 5D, 5F,
and 5G), as reported previously (Guo et al., 1997; Thomas
et al., 2000). Foci of PIN adjacent to invasive cancer consistently
showed both a reduced intensity of staining and a reduced
number of p27Kip1-positive cells compared with benign epi-
thelium (Figure 5G; data not shown), as reported previously (De
Marzo et al., 1998). In contrast, in 60% of the cases (15 of 25)
of isolated PIN without adjacent invasive cancer, p27Kip1 staining
was of similar intensity to adjacent benign epithelium (Figure 5B)
and was present in a higher percentage of cells compared to
benign epithelium (Figures 5D and 5G). The mean percentage
of cells staining positively for p27Kip1 was 52.4% (range 38%–
82%) in this subset of PIN and 42.9% (range 32%–50%) in the
secretory cells of adjacent benign epithelium (p < 0.001)
(Figure 5G). Thus, we confirmed that the increase in p27Kip1 in
murine models of prostate cancer also occurs in primary human
prostate cancers.
Figure 5. Stabilization of p27Kip1 in Human PIN
(A) Tissue section from normal human prostate stained with H&E.
(B) Normal prostate tissue section stained with antibody directed against
p27Kip1.
(C) Tissue section from human PIN stained with H&E.
(D) PIN tissue section stained with antibody directed against p27Kip1.
(E) Tissue section from human prostate cancer (CaP) stained with H&E.
(F) CaP tissue section stained with antibody directed against p27Kip1. Scale bar =
50 mM in (A)–(F).
(G) The number of p27Kip1-positive cells was determined in normal tissue, PIN,
PIN adjacent to CaP, and CaP. Data are presented as mean ± SEM.
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p27Kip1 Checkpoint Induces Senescence in PINHuman PIN Displays the Hallmark of Senescence
It has been reported that senescence is a hallmark of precursor
lesions in many different human tumors (Braig et al., 2005; Chen
et al., 2005; Collado et al., 2005; Michaloglou et al., 2005). In or-
der to determine whether a senescence checkpoint could be
identified in human PIN lesions, we performed pathological anal-
ysis of 21 frozen tissue samples from prostates with documented
PIN. The PIN lesions were documented in 7 of the 21, and senes-
cence was investigated by b-gal staining. Indeed, 4 of the 7 iden-
tified PIN lesions showed considerably more b-gal activity when
compared to nondysplastic epithelial cells in the same tissue
sections (Figures 6A and 6B). In addition, we characterized 44
human PIN lesions obtained from specimens without adjacent
cancer, with normal counterparts from paraffin-embedded tis-
sue sections. IHC and quantitative analysis by spectral imaging
of HP1a and HP1g showed increased levels of both markers in
PIN lesions when compared to normal ducts (Figures 6C–6F;
Figure S5D).
Induction of p27Kip1 during Detachment and Inhibition
of Cell-Cell Contact in Human Primary Prostate
Epithelial Cells
The PIN phenotype inAKT1-Tg mice is characterized by disorga-
nization of luminal epithelial cells, including loss of appropriate
cell polarization (see Majumder et al., 2004 and Figure 7A). In ad-
dition, in PIN lesions, numerous prostate epithelial cells are no
longer in tight contact with the basement membrane or with
nearby basal cells. These observations raised the possibility
that epithelial cell detachment may trigger upregulation of
p27Kip1 protein. To address this possibility, we turned to primary
human prostate epithelial cells (PrECs) engineered to express
SV40 large T antigen, the catalytic subunit of human telomerase
(hTERT), and the AR (Berger et al., 2004; Garraway et al., 2003).
These immortalized cells, PrEC-LEAR, were then transduced
with a retrovirus encoding Myr-Akt to create PrEC-LEKAR cells.
Next, these cells were plated on standard culture plates, on low-
adhesion coated plates, or in suspension, and protein extracts
were prepared after 24, 48, and 96 hr. In both cell lines, cell de-
tachment led to a significant increase in p27Kip1 that was more
notable in Akt-expressing cells (Figure 7C). These data support
the notion that detachment of human prostate epithelial cells, ei-
ther with or without Akt expression, leads to induction of p27Kip1.
Similar results were also obtained in Rat1 fibroblasts trans-
formed with Myr-AKT1 (Figure 7B).
E-cadherin, a member of the cadherin family, mediates epithe-
lial cell-cell interactions and maintains normal architecture and
polarity of epithelial cells in tissue. It also plays an important
role in the progression of many human cancers, including pros-
tate cancer. We asked whether inhibition of cell-cell contact is
sufficient to induce p27Kip1 stabilization in human primary pros-
tate cancer cells. Suppression of E-cadherin expression in
PrECs resulted in an inhibition of the normal architecture of
cell-cell contact (Figure 7E) and increased the level of p27Kip1
protein (Figure 7D).
DISCUSSION
Cancer is characterized by a series of transitions from preneo-
plastic lesions to invasive cancer and finally metastatic disease.A great deal of emphasis has been placed on defining these
events and understanding the disease progression at the molec-
ular level in metastatic settings. However, less attention has
been paid to the earlier transition points. It is not clear whether
overcoming certain phenotypic transitions is only linked to
checkpoints triggered by specific oncogenic mechanisms or
whether such phenotypic transitions intrinsically raise specific
checkpoint barriers that must be overcome. The angiogenic
switch (as an example) or the epithelial-mesenchymal transition
might represent such barriers or checkpoints to phenotypic tran-
sitions where tumors must acquire new properties in order to
progress (Hanahan and Folkman, 1996).
We have studied the phenotypic transition between PIN and
invasive cancer in a model of prostatic intraepithelial neoplasia
resulting from transgenic activation of AKT. Here we show that
in AKT1-transgenic and Pten homozygous mice, the PIN pheno-
type is associated with increased levels of p27Kip1 and the induc-
tion of markers of senescence. In order to determine whether the
induction of p27Kip1 was causally related to the block in pheno-
type progression, we studied the results of genetic inactivation
of Cdkn1b in the context of AKT1-Tg mice. Loss or downregula-
tion of p27Kip1 led to increased proliferative rates, loss of senes-
cence markers, and progression of the PIN phenotype to
Figure 6. Markers of Cellular Senescence Are Elevated in Human
PIN
(A and B) Frozen sections of normal human prostate (A) and PIN (B) were sub-
jected to b-gal and H&E staining. Blue staining indicates b-gal activity; H&E
was used as a counterstain to visualize the PIN lesion.
(C and D) Tissue sections from paraffin-embedded normal human prostate
and PIN lesions were stained with antibodies against HP1a (C) and HP1g
(D). Scale bar = 50 mM in (A)–(D) (100 mM in insert).
(E and F) Average area of HP1a-positive (E) and HP1g-positive (F) stain
was measured in both PIN lesion and normal tissue. Data are presented as
mean ± SD.Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc. 151
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p27Kip1 Checkpoint Induces Senescence in PINinvasive cancer. These latter data are consistent with prior data
showing that genetic inactivation of Cdkn1b in the context of
Pten+/ mice produces an invasive cancer phenotype (Di Cristo-
fano et al., 2001).
Cellular senescence opposes neoplastic transformation trig-
gered by activation of oncogenic pathways both in vitro and
in vivo (Chen et al., 2005; Collado et al., 2005). Inhibition of
cellular proliferation in premalignant lesions in mouse and hu-
Figure 7. Disruption of Cellular Polarization and Adhesion Is Associ-
ated with Upregulation of p27Kip1 Level
(A) VPs of WT and AKT1-Tg mice stained with ZO-1 antibody and imaged by
confocal microscope. Scale bar = 50 mM.
(B) Rat embryonic fibroblasts stably transfected with either vector or Myr-
AKT1 were cultured under adherent or suspension conditions. Protein lysates
were prepared and immunoblotted with antibodies directed against p27Kip1
(upper panel), phospho-Akt (S473) and phospho-GSK3a and b (middle panel),
and tubulin (lower panel).
(C) Protein lysates were prepared from primary human epithelial cells (LEAR
and LEKAR) cultured under adherent (Ad) or suspension (Susp) conditions. Im-
munoblot analysis was performed using antibodies directed against p27Kip1
(upper panel), phospho-Akt (S473) (middle panel), and tubulin (lower panel).
(D) LEAR cells were transduced with three different shRNAs against E-cad-
herin and shGFP as a control. Cells were harvested 2 days postselection,
and total protein lysates were prepared. Western blot analysis for E-cadherin
(upper panel), p27Kip1 (middle panel), and actin (lower panel) was performed.
(E) LEAR cells transduced with E-cadherin shRNAs and shGFP control were
grown in plates, and images were acquired 2 days postselection. Scale bar =
100 mM.152 Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc.man might be the result of oncogene-induced senescence
(Braig et al., 2005; Chen et al., 2005; Collado et al., 2005; Mi-
chaloglou et al., 2005). Chen et al. (2005) have shown that
cells undergo senescence in preneoplastic lesions in Pten-de-
ficient prostate. In addition, myristoylated Akt induces cellular
senescence in primary murine embryonic fibroblasts (Miyau-
chi et al., 2004). These published data suggested that the se-
nescence induced by loss of function of Pten is a result of
Akt activation but requires p53. In contrast to these findings,
more recent data demonstrate that cellular senescence due
to the loss of another tumor suppressor gene, VHL, is p53 in-
dependent (Young et al., 2008). Thus, the cooperating events
that contribute to the induction of senescence in preneoplas-
tic lesions that occurs as a result of loss of a tumor suppres-
sor gene or activation of an oncogene may be diverse.
In our model, we asked whether p27Kip1 and the senescence
checkpoint are specifically associated with oncogene activation
or with a phenotype-induced checkpoint. Careful dissection of
the phenotype in response to mTOR inhibition coupled to mea-
sures of pathway activation for both Akt and mTOR demon-
strated that increased p27Kip1 (Figures 4M–4O) and cellular se-
nescence (Figures 4J–4L) are dependent on the preneoplastic
lesions and do not depend directly upon either Akt or mTOR ac-
tivation. Similarly, we did not find any correlation between mTOR
activation and levels of p27Kip1 or senescence markers in a sub-
set of clinical samples with PIN. However, correlation between
loss of PTEN staining and activation of mTOR in these clinical
PIN specimens was observed (Figure S5; data not shown).
Thus, it appears that a PIN-dependent p27Kip1 checkpoint rather
than an oncogene-induced checkpoint is enacted in the AKT1-
Tg mice. Moreover, in Myc-Tg mice, p27Kip1 elevation was also
seen in the PIN lesions. Thus, the checkpoint is apparently in-
duced as a consequence of phenotypic perturbation that can
be brought about by multiple upstream mechanisms. The appar-
ent phenotype dependence of the p27Kip1 checkpoint may at
least in part explain the synergy noted when Cdkn1b is geneti-
cally inactivated in the context of multiple other oncogenic or tu-
mor suppressor manipulations and the high frequency of down-
regulation of p27Kip1 in human tumors.
It is not yet clear specifically what perturbation associated with
the PIN phenotype might trigger accumulation of p27Kip1. Many
possibilities, including loss of matrix association, loss of polarity,
or loss of luminal-basal cell interactions, could be considered.
Mammoto et al. (2004) previously found that restriction of extra-
cellular matrix adhesion and inhibition of cell spreading are asso-
ciated with induction of p27Kip1 and G1 arrest. In keeping with
this notion, we found that in human prostate epithelial cells,
p27Kip1 was induced under conditions of contact-free growth
(Figures 7B and 7C). Recent data suggest that when E-cadherin
is lost, cells fail to polarize (Capaldo and Macara, 2007). Here we
showed that downregulation of E-cadherin expression by shRNA
in primary human prostate cancer cells increased the level of
p27Kip1 and disrupted cell-cell interactions (Figures 7D and 7E).
We speculate that similar conditions might be recapitulated by
loss of contact between epithelial cells and the basement mem-
brane in vivo, as E-cadherin has been shown to be downregu-
lated in human PIN as well as subsequent carcinoma (Jaggi
et al., 2005). In addition, we have previously shown that PIN
lesions in AKT1-Tg mice lose oriented zona occludens-1
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jumder et al., 2004). In fact, loss of polarity and detachment
from basal cells and the basement membrane are characteristic
of PIN. Links between the regulation of polarity and cell-cycle
control are increasingly being recognized, particularly in tying
cell orientation to oriented cell division (reviewed in Wodarz,
2001). Intriguingly, disruption of the polarized cytoskeleton and
of bud formation in Saccharomyces cerevisiae is linked to delays
in cell-cycle progression, dependent at least in part on Swe1,
a CDK-inhibitory kinase (reviewed in Lew, 2003). Whether regu-
lation of cell polarity is tied to a senescence checkpoint remains
to be determined.
Importantly, these data are highly relevant to human prostate
cancer. Indeed, we show that p27Kip1 is overexpressed in human
PIN not associated with invasive cancer, presumably represent-
ing the earliest phase of neoplastic transformation. In contrast,
PIN adjacent to invasive cancer, where checkpoint loss may
have already occurred, is associated with low levels of p27Kip1.
The role of p27Kip1 in this process is further supported by
a body of data showing that loss of p27Kip1 is commonly found
in human cancers (Chu et al., 2008) and that invasive tumor cells
specifically degrade p27Kip1. This in turn results in increased
CDK2 activity (Loda et al., 1997).
As many as 30% of men with a diagnosis of PIN on biopsy are
subsequently found to harbor an invasive prostatic adenocarci-
noma on repeat biopsy (Gokden et al., 2005). Our findings there-
fore suggest that CDK inhibitors might have utility in preventing
cancer progression from in situ dysplasia to invasion. Indeed,
our group has previously shown that flavopiridol can in fact re-
duce the prevalence of esophageal cancer in a murine surgical
model of Barrett’s dysplasia and esophageal carcinoma in
Cdkn1b/ mice (Lechpammer et al., 2005). We have also dem-
onstrated that preinvasive lesions of metaplastic esophageal
mucosa in humans (Barrett’s-associated dysplasias) also exhibit
marked overexpression of p27Kip1 with subsequent loss as inva-
sion ensues, suggesting that upregulation of p27Kip1 may be
a checkpoint in other tissues as well (Singh et al., 1998). CDK in-
hibitors are in clinical trials for a number of human cancers. If
safety and efficacy can be established, prevention trials with
these agents in high-risk patients harboring preinvasive lesions
could be considered.
EXPERIMENTAL PROCEDURES
Generation of Compound Heterozygous Mice
Cdkn1b heterozygous mice (B6.129S4-Cdkn1btm1Mlf/J), generated by the
laboratory of James Roberts (Fred Hutchinson Cancer Research Center, Seat-
tle), were obtained from the Jackson Laboratory (Fero et al., 1996). The hetero-
zygous mice were bred to AKT1-Tg heterozygous mice (FVB-Tg/Pbsn-
Akt1wrs9) to generate F1 AKT1-Tg/Cdkn1b heterozygous mice. The compound
AKT1-Tg heterozygous/Cdkn1b heterozygous mice were intercrossed to gen-
erate the F2 colony, and the resulting offspring were used in this study. All pro-
cedures were performed according to protocols approved by the Institutional
Animal Care and Use Committee of the Dana-Farber Cancer Institute.
Genotyping, Dissections, and Preparation of Tissues
Isolation of genomic DNA from tail cuts or ear punches, PCR-based genotyp-
ing, prostate and genitourinary tract dissections, tissue fixation, and hematox-
ylin and eosin (H&E) stains were performed as described previously (Majumder
et al., 2003; Xu et al., 2007).Cdkn1b heterozygous and homozygous mice were
genotyped as described previously (Di Cristofano et al., 1998).Administration of RAD001 or BrdU
40-O-(2-hydroxyethyl)-rapamycin (RAD001; 10 mg/kg/day) was administered
as a microemulsion (Taesch and Niese, 1994) (2% w/w) diluted in double-dis-
tilled H2O (ddH2O) by oral gavage as described previously (Majumder et al.,
2004). Mice receiving BrdU were injected intraperitoneally with 50 mg/kg of
BrdU in PBS 12 hr prior to euthanasia and were sacrificed after immediate ven-
tricular perfusion with 4% buffered formaldehyde.
Immunohistochemical and Immunoblot Analysis
Mounted tissue sections (both human and murine) were hydrated, incubated
for 30 min with 3% H2O2 in methanol at room temperature, washed with
ddH2O and PBS, and heated in a microwave to 199
F in 1 mM EDTA
(pH 8.0) for 25 min (for anti-p27Kip1, anti-CK19, anti-phospho-Akt (S473),
anti-phospho-S6RP, anti-AR, and anti-BrdU staining) or in 10 mM citrate
buffer (pH 6.0) for 30 min (for anti-p63, anti-HP1a, and anti-HP1g staining).
Sections were blocked in 10% goat serum (Vector) for 30 min; incubated
with anti-phospho-Akt (S473) (1:400), anti-phospho-S6RP (1:400), anti-AR
(1:400) (Cell Signaling), anti-CK19 (1:200), anti-p27Kip1 (1:200), anti-p63
(1:100), anti-BrdU (1:200) (BD PharMingen), anti-HP1a (1:1000) (clone
15.19s2, Upstate), or anti-HP1g (1:1000) (clone 42s2, Upstate) in 1% BSA
for 12 hr at 4C; washed with PBS; and incubated with secondary antibody
(1:200) (Vector Laboratories) for 30 min. Antigen-antibody complexes were
detected with an ABC kit (Vector Laboratories) or by 3,30-diaminobenzidine
(DAB) followed by methyl green counterstaining (for HP1a and HP1g). Frozen
sections (5 mm thick) of VPs of different genotypes and frozen human prostate
specimens were stained with b-gal (Calbiochem) and CK14. Protein extracts
and immunoblots were prepared as described previously (Majumder et al.,
2003). Anti-phospho-Akt (S473), anti-phospho-GSK3 (Cell Signaling), anti-
p27Kip1 (BD PharMingen), anti-E-cadherin (BD PharMingen), and anti-tubulin
(B-5-1-2) (Sigma) were used at 1:1000.
Scoring of p27Kip1 Immunohistochemistry in Human
Prostate Specimens
Sixty-nine formalin-fixed cases of PIN were examined, including 44 cases of
PIN with adjacent invasive CaP and 25 cases in patients without the histologic
diagnosis of invasive cancer. All human tissues were collected from Brigham
and Women’s Hospital (Boston) using a protocol approved by the Partners Hu-
man Research Committee Institutional Review Board. Sections were stained
with anti-p27Kip1 antibody as described above. Three hundred cells from rep-
resentative PIN foci, adjacent benign prostatic epithelium, and invasive cancer
were counted, and the number of cells with nuclear p27Kip1 staining was deter-
mined. Only cells in which the staining intensity was equal to or greater than the
adjacent normal secretory prostatic epithelium were considered positive.
Twenty-one frozen human prostate biopsy tissues were stained with b-gal,
and the presence of PIN was detected in seven samples. Higher levels of b-gal
positivity compared to the adjacent normal cells were present in four of these
seven.
Scoring of HP1a and HP1g Staining in Mouse and Human
Prostate Specimens
Both human (n = 44) and mouse (n = 20) prostate tissues were stained with
anti-HP1a and HPg. Since HP1 differential staining was low, localization and
relative intensity were assessed using spectral imaging methods similar to
those described previously (Byers et al., 2007). Spectral imaging and digital
spectral cube deconvolution were performed using a CRi Nuance spectral an-
alyzer (Cri, Inc.) and the associated software package. Image analysis and
stain intensity quantitation were performed on the appropriate spectra using
NIH ImageJ (http://rsb.info.nih.gov/ij/). Images were acquired at 203 objective
magnification, and image intensities were normalized to a threshold value.
Staining above the threshold intensity was considered positive, and the posi-
tive area within fields of 20 nuclei was measured.
Human Prostate Cell Lines, Rat Fibroblast Cells,
and E-Cadherin Knockdown
Human primary prostate epithelial cells (PrECs) expressing SV40 large T anti-
gen, hTERT, and AR without (PrEC-LEAR) or with myristoylated FLAG-AKT1
(PrEC-LEKAR) (Berger et al., 2004) were plated on ultra-low attachment plates
(Corning) at a density of 200,000 viable cells/ml in serum-free media (PrEGM)Cancer Cell 14, 146–155, August 12, 2008 ª2008 Elsevier Inc. 153
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centrifugation (800 rpm) after 1, 2, and 4 days and were dissociated by incuba-
tion for 10 min in 0.05% trypsin, 0.53 mM EDTA (Invitrogen). LEAR cells were
infected with three independent shRNAs against E-cadherin (shECad1, 50-
CCAGTGAACAACGATGGCATT-30; shECad2, 50-CCAAGCAGAATTGCTCAC
ATT-30; and shECad3, 50-CGATTCAAAGTGGGCACAGAT-30) and control
shGFP. Cells were harvested 2 days postselection. PrECs were lysed by son-
ication in 1.25% SDS, 0.0125 NaPO4 (pH 7.2), 50 mM NaF, 2 mM EDTA, 1.25%
NP-40, 1 mM sodium vanadate with protease inhibitors (Roche).
Rat embryonic fibroblast cells were infected with Myr-AKT1, and a stable
cell line was established by single-cell dilution. Expression of Myr-Akt was de-
termined by immunoblot analysis using an antibody against phospho-Akt
(S473). These cells were grown either in adherent cell culture dishes or in sus-
pension for 24 hr. Cells were lysed and protein was isolated as described pre-
viously (Majumder et al., 2003).
Statistical Analysis
One-way ANOVA was used to test for differences in cell proliferation and IHC
scores between different genotypes.
SUPPLEMENTAL DATA
The Supplemental Data include five figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/14/2/146/DC1/.
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